Clofazimine; the past or the future for TB treatment
Event details
| Date | 10.06.2013 |
| Hour | 11:00 › 12:00 |
| Speaker | Prof. Jacques Grosset |
| Location | |
| Category | Conferences - Seminars |
Clofazimine (CFZ) is sometimes administered to patients with multidrug-resistant tuberculosis (MDRTB),
despite never having been evaluated for this purpose. We assessed the contribution of CFZ to a
second-line regimen in a mouse model of MDR-TB. The addition of CFZ resulted in culture-negative
lungs after 5 months of treatment, while mice receiving the non-CFZ-containing regimen remained
positive after 9 months. The proportion of relapses was 3/15, 3/15, 5/15, 1/14 and 1/15 among mice
treated with clofazimine for 5, 6, 7, 8 and 9 months, respectively (p>0.1). On average, the rate of
relapse-free cure among clofazimine-treated mice was 82.4%. In conclusion, the clofazimine
contribution was spectacular in the present experimental conditions.
despite never having been evaluated for this purpose. We assessed the contribution of CFZ to a
second-line regimen in a mouse model of MDR-TB. The addition of CFZ resulted in culture-negative
lungs after 5 months of treatment, while mice receiving the non-CFZ-containing regimen remained
positive after 9 months. The proportion of relapses was 3/15, 3/15, 5/15, 1/14 and 1/15 among mice
treated with clofazimine for 5, 6, 7, 8 and 9 months, respectively (p>0.1). On average, the rate of
relapse-free cure among clofazimine-treated mice was 82.4%. In conclusion, the clofazimine
contribution was spectacular in the present experimental conditions.
Practical information
- Informed public
- Free